Elizabeth M. Gaughan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Elizabeth M. Gaughan has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Alejandro A. Gru
Department of Dermatology, Division of Dermatopathology Columbia University Irving Medical Center/NewYork‐Presbyterian New York New York USA
1 shared publication - Anne M. Stowman
Department of Pathology, Division of Anatomic Pathology, University of Virginia Health System, PO Box 800716, Charlottesville, 22908 VA USA
1 shared publication - Craig L. Slingluff
Department of Surgery/Division of Surgical Oncology and the Human Immune Therapy Center, Cancer Center, University of Virginia, Charlottesville, USA
1 shared publication - Joshua E. Reuss
Georgetown University, Washington, DC
1 shared publication - Krishi V. Peddada
University of Virginia Department of Ophthalmology 1300 Jefferson Park Ave. Charlottesville, VA, 22903, USA
1 shared publication - Naveen Kumar Ambati
University of Virginia School of Medicine, 200 Jeanette Lancaster Way, Charlottesville, VA, 22903, USA
1 shared publication
Latest Publications
- Open Access
- 31 January 2022
- Published by Elsevier in American Journal of Ophthalmology Case Reports
- Vol. 25, 101351
Multiple evanescent white dot syndrome-like reaction associated with ipilimumab and nivolumab immune checkpoint inhibitor therapy for metastasis of choroidal melanoma
- 31 January 2022
- Published by Elsevier in American Journal of Ophthalmology Case Reports
- Vol. 25, 101351
Open AccessMultiple evanescent white dot syndrome-like reaction associated with ipilimumab and nivolumab immune checkpoint inhibitor therapy for metastasis of choroidal melanoma
- Open Access
- 20 December 2016
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 4 (1) , 94
Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature
Background We report a case of sarcoidosis in a patient with metastatic melanoma managed with combination ipilimumab/nivolumab. Sarcoid development has been linked with single agent immunotherapy but, to our knowledge, it has not been reported with combination ipilimumab/nivolumab treatment. This case raises unique management challenges for both the melanoma and the immunotherapy-related toxicity. Case presentation A 46 year old Caucasian female with M1c-metastatic melanoma was managed with ipilimumab/nivolumab combination. Patient experienced response in baseline lesions but developed new clinical and radiographic findings. Biopsy of new lesions at two different sites both demonstrated tumefactive sarcoidosis. Staining of the biopsy tissue for PD-L1 expression demonstrated strong PD-L1 staining of the histiocytes and lymphocytes within the granulomas. Monotherapy nivolumab was continued without progression of sarcoid findings or clinical deterioration. Conclusions Tissue biopsy for evaluation of new lesions on immunotherapy is an important step to help guide decision making, as non-melanoma lesions can mimic disease progression.
- 20 December 2016
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 4 (1) , 94
Open AccessSarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature
Background We report a case of sarcoidosis in a patient with metastatic melanoma managed with combination ipilimumab/nivolumab. Sarcoid development has been linked with single agent immunotherapy but, to our knowledge, it has not been reported with combination ipilimumab/nivolumab treatment. This case raises unique management challenges for both the melanoma and the immunotherapy-related toxicity. Case presentation A 46 year old Caucasian female with M1c-metastatic melanoma was managed with ipilimumab/nivolumab combination. Patient experienced response in baseline lesions but developed new clinical and radiographic findings. Biopsy of new lesions at two different sites both demonstrated tumefactive sarcoidosis. Staining of the biopsy tissue for PD-L1 expression demonstrated strong PD-L1 staining of the histiocytes and lymphocytes within the granulomas. Monotherapy nivolumab was continued without progression of sarcoid findings or clinical deterioration. Conclusions Tissue biopsy for evaluation of new lesions on immunotherapy is an important step to help guide decision making, as non-melanoma lesions can mimic disease progression.